Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Exact Sciences Corporation    EXAS

EXACT SCIENCES CORPORATION

(EXAS)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/14/2020 02/18/2020 02/19/2020 02/20/2020 02/21/2020 Date
98.18(c) 99.6(c) 102.52(c) 102.64(c) 99.98(c) Last
1 477 898 1 394 388 1 584 789 1 290 424 1 034 061 Volume
+3.61% +1.45% +2.93% +0.12% -2.59% Change
More quotes
Financials (USD)
Sales 2020 1 631 M
EBIT 2020 -208 M
Net income 2020 -216 M
Debt 2020 673 M
Yield 2020 -
Sales 2021 2 071 M
EBIT 2021 10,6 M
Net income 2021 -14,0 M
Debt 2021 563 M
Yield 2021 -
P/E ratio 2020 -68,4x
P/E ratio 2021 -843x
EV / Sales2020 9,48x
EV / Sales2021 7,42x
Capitalization 14 794 M
More Financials
Company
Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. Its Cologuard test... 
More about the company
Surperformance© ratings of Exact Sciences Corporation
Trading Rating : Investor Rating :
More Ratings
Latest news on EXACT SCIENCES CORPORATION
02/21EXACT SCIENCES : Management's Discussion and Analysis of Financial Condition and..
AQ
02/19EXACT SCIENCES : SEC Filing - CT ORDER
PU
02/11EXACT SCIENCES : 4Q Earnings Snapshot
AQ
02/06EXACT SCIENCES CORPORATION : annual earnings release
01/31EXACT SCIENCES CORP : Amendments to Articles of Inc. or Bylaws; Change in Fiscal..
AQ
2019EXACT SCIENCES CORP : Other Events (form 8-K)
AQ
2019EXACT SCIENCES CORP : Completion of Acquisition or Disposition of Assets, Regula..
AQ
2019GENOMIC HEALTH : Exact Sciences Completes Combination with Genomic Health, Creat..
AQ
2019EXACT SCIENCES : Management's Discussion and Analysis of Financial Condition and..
AQ
2019EXACT SCIENCES : 3Q Earnings Snapshot
AQ
2019EXACT SCIENCES : Management's Discussion and Analysis of Financial Condition and..
AQ
2019EXACT SCIENCES CORP : Entry into a Material Definitive Agreement, Financial Stat..
AQ
2019EXACT SCIENCES : buys Genomic in $2.8bn deal
AQ
2019Diagnostic company Exact Sciences to buy Genomic Health in $2.8 billion deal
RE
2019EXACT SCIENCES : Cancer diagnostic firms to join in $2.8 billion deal
AQ
More news
News in other languages on EXACT SCIENCES CORPORATION
02/06EXACT SCIENCES CORPORATION : publication des résultats annuels
02/06EXACT SCIENCES CORPORATION : Veröffentlichung des Jahresergebnisses
2019STOCK MARKET PARIS : Attention, semaine très chargée !
2019EN DIRECT DES MARCHES : Sanofi, Airbus, Air France KLM, CNP, Refinitiv, Mylan..
2017EXACT SCIENCES CORPORATION : Veröffentlichung des Halbjahresergebnisses
More news
Analyst Recommendations on EXACT SCIENCES CORPORATION
More recommendations
Sector news : Bio Diagnostics & Testing
02/20Anglo American Discloses All Mine Deaths in Industry Shift--Update
DJ
02/20Anglo American Discloses All Mine Deaths in Industry Shift -- Update
DJ
02/20Anglo American Discloses All Mine Deaths in Industry Shift
DJ
02/20GlaxoSmithKline Invests $50 Million in Biotech Startup's Cell-Therapy Program
DJ
02/19Five Prime Therapeutics In License Agreement with Seattle Genetics
DJ
More sector news : Bio Diagnostics & Testing
Chart EXACT SCIENCES CORPORATION
Duration : Period :
Exact Sciences Corporation Technical Analysis Chart | EXAS | US30063P1057 | MarketScreener
Technical analysis trends EXACT SCIENCES CORPORATION
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 16
Average target price 122,40  $
Last Close Price 99,98  $
Spread / Highest target 35,0%
Spread / Average Target 22,4%
Spread / Lowest Target 5,02%
EPS Revisions
Managers
NameTitle
Kevin T. Conroy Chairman, President & Chief Executive Officer
Ana Hooker Senior Vice President-Operations
Jeffrey T. Elliott Chief Financial Officer
Barry M. Berger Co-Chief Medical Officer & Head-Medical Affairs
Graham Peter Lidgard Chief Science Officer, SVP-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
EXACT SCIENCES CORPORATION10.99%14 794
GUARDANT HEALTH, INC.13.66%8 340
GENSCRIPT BIOTECH CORPORATION-1.24%4 230
IOVANCE BIOTHERAPEUTICS, INC.-6.14%3 279
INVITAE CORPORATION43.21%2 230
MIRACA HOLDINGS INC.-0.07%1 416